key: cord-0958318-axaq7abs authors: Linssen, Joachim; Schapendonk, Claire; Münster, Marion; Daemen, Paul; Rahamat‐Langendoen, Janette; Wertheim, Heiman title: A method comparison study of the high throughput automated HISCL® SARS‐CoV‐2 antigen assay using nasopharyngeal swab samples from symptomatic and asymptomatic subjects against conventional RT‐PCR date: 2022-03-08 journal: J Med Virol DOI: 10.1002/jmv.27679 sha: f71c2d307227cd137e4295710754a114a45e442b doc_id: 958318 cord_uid: axaq7abs Our study aim was to evaluate the performance of the automated Sysmex HISCL® severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) antigen assay against reverse‐transcription polymerase chain reaction (RT‐PCR). We tested 277 remnant frozen nasopharyngeal swab samples, stored in universal transport medium (UTM), yielding a sensitivity of 94.9% against historical RT‐PCR results with cycle threshold (C (t)) < 30, and a sensitivity of 76.7% for C (t) < 35, and specificity of 100% (all C (t) values) confirming compatibility of UTM‐diluted samples with the assay system. Thereafter, we prospectively collected 141 nasopharyngeal swab samples in UTM from healthcare workers and 1369 paired swabs (400 UTM; 969 dry) from individuals at a public health testing center, with the first swab (UTM) reserved for RT‐PCR, yielding a positivity rate of 4.6%. HISCL assay performance using UTM swabs was superior to dry swabs, with a sensitivity of 100% (95% confidence interval [CI] 71.5%–100%) at C (t) < 30 versus 92.3% (95%CI 81.5%–97.9%), and a specificity of 99.3% (95% CI 98.1–99.89) against 83.3% (95%CI 80.7%–85.6%). We conclude that this antigen assay is suitable for high throughput facilities where the primary indication for testing is to rule out infection with low RT‐PCR C (t) values (proxy for high viral loads) to curb viral spread. swab samples, through global scientific community collaboration. 3 These early protocols laid the foundation for case confirmation, but the rapid spread and geographic scale of infection soon overwhelmed the diagnostic capacity of laboratories equipped to conduct such relatively complex in-house molecular tests. This provided the impetus for the unprecedented speed of development of simplified commercial RT-PCR-based COVID-19 testing kits. 4 Access was facilitated by fast-tracked emergency use listing by the World Health Organization (WHO) 5 or emergency use authorization by the United States Food and Drug Administration. 6 Numerous SARS-CoV-2 RT-PCR kits have since become available from multiple manufacturers. Accurate and rapid widescale COVID-19 testing is essential to contain this continuously evolving pandemic. Viral nucleic acid detection by RT-PCR, with its excellent sensitivity and specificity, makes it the most reliable SARS-CoV-2 detection method. 7 However, a major limitation is the sophisticated laboratory infrastructure requirement and relatively long result turnaround time. 8 Pre-analytical nucleic acid extraction, sometimes manual, is required, and most commercial kits are optimized for batch testing, taking 3-4 h on average. As the pandemic evolved, indications for testing expanded from diagnosis for symptomatic individuals, to screening of asymptomatic individuals as part of public health measures to re-open economies, on the premise that asymptomatic and presymptomatic individuals can transmit the virus. 9 Consequently, it became evident that RT-PCR testing accessibility was insufficient, 10 paving the way for the next wave of diagnostic tool development, namely rapid antigen tests (RAT). 11 Antigen tests detect viral proteins directly, in contrast to RT-PCR-based viral nucleic acid detection requiring thermal amplification. 4 Antigen tests are thus inherently less sensitive than RT-PCR for SARS-CoV-2 detection, but this is offset by superior accessibility. RAT are mostly lateral flow assays in single test formulation, with or without a strip reader, providing results within approximately 15 min, simple to use, and thus suitable for use outside of laboratories. 12 Both RT-PCR and antigen tests detect the presence of viral particles, but neither can confirm active infection with a live virus capable of infecting others. 13 Only viral culture, beyond the realm of routine diagnostics, can achieve that. RT-PCR cycle threshold (C t ) values, which provide a viral load approximation, 14 have been used as a surrogate to estimate the probability of infectivity, the higher the C t value the lower the viral load and the lower the likelihood of infectivity. A C t value of approximately 30 is generally accepted as the threshold beyond which transmission is unlikely, 15, 16 an important consideration where the primary indication of screening tests is to identify asymptomatic infected individuals capable of onward transmissibility. Head-to-head comparisons with established lab-based RT-PCR methods, the de facto gold standard, show that RAT sensitivity varies substantially amongst manufacturers. Whilst some have shown excellent performance 17,18 many fail to detect RT-PCR positive samples with C t > 25. [19] [20] [21] [22] Although RAT has revolutionized access, their suboptimal sensitivity limits their effectiveness in curbing viral spread. In contrast, automated immunoassay antigen tests provide high throughput and have been reported to have better sensitivity than RAT for C t > 25. 23 Although automated antigen tests, like RT-PCR are laboratory-based tests, they do not require highly skilled operators, can be conducted within routine clinical laboratories, and have a significantly shorter time to result availability. As such automated antigen testing, although not yet widely established, has the potential to fill an important gap in the COVID-19 diagnostic landscape. Here, we present a performance evaluation of the HISCL ® SARS-CoV-2 antigen assay on the HISCL ® -5000 analyser (Sysmex Corporation), compared with routine RT-PCR testing on nasopharyngeal swab samples obtained from symptomatic healthcare workers tested as part of COVID-19 workplace requirements and individuals presenting to a public health testing center. Here, the original aim was to compare dry swab (study-specific sample) and UTM swab (routine sample) antigen testing, with RT-PCR (UTM). Two nasopharyngeal swabs were collected from consenting adults presenting for testing (irrespective of symptoms). The first swab was placed in 1.5 ml UTM, the second swab was kept dry and placed in the HISCL specific buffer, exclusively for antigen testing, upon receipt in the laboratory. Logistically it proved impossible to test the UTM sample with the antigen assay as the routine RT-PCR testing was conducted at a location remote to RadboudUMC. This study part was thus limited to a dry swab antigen test comparison with RT-PCR testing on a separate, but simultaneously collected UTM swab sample. The TIB Modular Sarbeco E gene assay (TibMolbiol) was used for routine RT-PCR testing throughout the study as per laboratory standard operating procedures. Testing was conducted on the Roche Flow Solution for molecular diagnostics platform for all prospectively collected samples, and most of the bio-banked samples. Due to material shortages, the laboratory temporarily switched to using the Roche Cobas 4800 system, during the period of the bio-bank archive samples accumulation. Samples were selected from the freezer archive as per the selection criteria and thawed on the day of testing. RT-PCR was repeated on the first 50 thawed specimen samples to ensure that viral particle degradation during storage did not unduly bias test performance. The prestorage RT-PCR repeat testing Ct values of the previously frozen sample were compared. As C t values were similar, repeat RT-PCR was only performed on the remaining samples if the results were discordant. As the original HISCL antigen assay was designed for dry swab testing, we tested various UTM with extract solution dilutions on a subset of samples to find the optimal ratio for testing without undue loss of sensitivity due to dilution (too much UTM) and invalid results (insufficient extract solution buffer), settling on 300 µl UTM sample in 500 µl HISCL extract solution for the method comparison and all other testings. HISCL antigen testing was conducted as per manufacturer instructions, with the adaptation described above for UTM swabs. The testing procedure followed is outlined in Figure 1A . Additionally, we conducted repeatability testing using 10 replicate measurements for three sample pools: PCR negative, low viral load C t~2 7, and high viral load C t~2 0 and stability testing with daily testing over 6 days using a pool of positive samples (C t 24-29) at room temperature (~20°C) and 4°C. Information on swab type used for collection and whether storage was in UTM or GLY was not available for individual samples. 2.5.2 | Part 2: Prospective testing of fresh nasopharyngeal swabs Nasopharyngeal swabs were collected in accordance with standard local procedures using Copan FLOQSwab Minitip swabs. The workflow for the prospective testing of the fresh nasopharyngeal swab samples collected within the hospital setting and the PHTC is shown in Figure 1B -D. Dry swabs received at RadboudUMC laboratory were stored at approximately 4°C and placed within HISCL extract solution within 24 h of collection. If these samples, together with those received in UTM were not tested on the day of collection, they were stored at −70°C for ≤72 h before testing. HISCL antigen testing was conducted as per manufacturer instructions, with the adaptation for the UTM swabs previously described. We additionally tested a sub-set of samples using filtration only, instead of centrifugation and filtration, to assess if preanalytical processing could be shortened without compromising analytical performance. Table 3 . We confirmed that blood contamination did not influence antigen testing as the 8.2% (82/969) visibly bloody samples after dry swab immersion in extract solution tubes showed no significant difference in performance (p > 0.05). The correlation between antigen assay and RT-PCR results for all 1787 samples tested in this study, with an overall 16.7% RT-PCR positivity rate, is shown in Figure 3 . Predictive values were calculated for the prospective arm of the study using 5% and 25% disease prevalence rates (Table 4) . T A B L E 1 Characteristics and SARS-CoV-2 testing results of nasopharyngeal swab samples frozen in 3 ml viral transport medium (Part 1) RT-PCR, with its unsurpassed diagnostic accuracy, remains the undisputed gold standard for the detection of viral particles. 14 RAT although highly accessible, easy-to-use and rapid, are not scalable, and have highly variable sensitivity, ranging from 58% in asymptomatic individuals to 72% during the first few days of symptoms, and 94.5% for C t ≤ 25, based on a meta-analysis incorporating 48 studies. 25 For testing to be fully effective, it must be accurate and accessible. A recent study has suggested that antigen assays performed on high throughput immunoanalysers may offer a viable solution for patient screening, or in situations where RT-PCR testing is not readily available. 26 In this present study, we evaluated the performance of the au- Although there is no reference standard for infectiousness, evidence exists that viral transmission is far less likely at C t ≥ 30, 15 hence this threshold has been adopted by some healthcare authorities to gauge transmission risk. 27 Abbreviations: CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. a The NPV and PPV for dry swab testing was calculated using the sensitivity and specificity values obtained for samples processed strictly in accordance with manufacturer instructions. LINSSEN ET AL. | 9 ACKNOWLEDGMENTS Sysmex Europe GMBH funded the study and provided the HISCL ® -5000 analyser, related reagents and nasopharyngeal swabs and transport tubes for the duration of the study. Joachim Linssen and Marion Münster are full-time employees of Sysmex Europe GMBH who funded the study. The other authors have no conflicts of interest to declare. The use of the frozen bio-banked samples and residual nasophar- The data that support the findings of this study are available from the corresponding author upon reasonable request. http://orcid.org/0000-0002-5366-4842 A new coronavirus associated with human respiratory disease in China Diagnostic Detection of 2019-nCoV by Real-Time RT-PCR. World Health Organization Considerations for diagnostic COVID-19 tests Emergency Use Listing for In vitro diagnostics (IVDs) Detecting SARS-CoV-2. World Health Organization In Vitro Diagnostics EUAs -Molecular Diagnostic Tests for SARS-CoV-2. United States Food and Drug Administration Real-time RT-PCR in COVID-19 detection: issues affecting the results Molecular diagnostic technologies for COVID-19: limitations and challenges SARS-CoV-2 viral load in upper respiratory specimens of infected patients The explosion of new coronavirus tests that could help to end the pandemic Antigen-Detection in the Diagnosis of SARS-CoV-2 Infection: Interim Guidance Scaling up COVID-19 rapid antigen tests: promises and challenges Duration of culturable SARS-CoV-2 within different specimens among mild and severe COVID-19 patients: a longitudinal study Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Can the cycle threshold (Ct) value of RT-PCR test for SARS CoV2 predict infectivity among close contacts? SARS-CoV-2 rapid antigen test: fast-safe or dangerous? An analysis in the emergency department of an university hospital Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand Comparison of the SARS-CoV-2 Rapid antigen test to the real star Sars-CoV-2 RT PCR kit Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and meta-analysis SARS-CoV-2 rapid antigen test: High sensitivity to detect infectious virus Evaluation of analytical performance of seven rapid antigen detection kits for detection of SARS-CoV-2 Virus Efficacy comparison of three rapid antigen tests for SARS-CoV-2 and how viral load impact their performance Head-to-head comparison of rapid and automated antigen detection tests for the diagnosis of SARS-CoV-2 infection COVID-19: Entlassungskriterien aus der Isolierung -Orientierungshilfe für Ärztinnen und Ärzte Entlasskriterien_A3_V11.pdf?sequence=1%26isAllowed=y Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection Multicenter evaluation of a fully automated high-throughput SARS-CoV-2 antigen immunoassay Health Strategic Command Group Q. Revised policy on use of PCR test Ct values for admission and discharge from isolation facilities Performance of an antigen-based test for asymptomatic and symptomatic SARS-CoV-2 testing at two university campuses -Wisconsin Comparison of automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313 nasopharyngeal swabs, including from seven serially followed patients Evaluation of the Elecsys SARS-CoV-2 antigen assay for the detection of SARS-CoV-2 in nasopharyngeal swabs Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. World Health Organization